Trials / Unknown
UnknownNCT02018757
Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC
Clinical Application Study of Transarterial Chemoembolization Containing Arsenic Trioxide in the Treatment of Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- Sponsor
- First Hospital of China Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine whether transarterial chemoembolization containing arsenic trioxide is safe and effective in the treatment of intermediate-stage hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TACE containing As2O3 | transarterial chemoembolization containing a mixture of 20mg of arsenic trioxide, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol |
| DRUG | TACE containing placebo | transarterial chemoembolization containing a mixture of 20mg of placebo, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2015-12-01
- First posted
- 2013-12-23
- Last updated
- 2014-05-28
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02018757. Inclusion in this directory is not an endorsement.